The ClearLLab test marks cell proteins with fluorescent dyes, which clinicians can further analyze on a flow cytometer instrument. The test detects cancerous cells in blood, bone marrow or lymph nodes and provides information about what type of leukemia or lymphoma is detected.
“This represents a major step forward for the hematology-oncology community,” said Alberto Gutierrez, PhD, director of the FDA’s Office of In Vitro Diagnostics. “Laboratories and healthcare professionals now have access to an FDA-validated test that provides consistent results to aid in the diagnoses of these serious cancers.”
More articles on supply chain:
FDA approves Scibase’s melanoma detection device: 3 things to know
New York City faces critical blood shortage
UPS to freeze 70k workers’ pensions: 3 things to know
